Results 61 to 70 of about 248,205 (145)

The DiSC assay - A cost-effective guide to treatment for chronic lymphocytic leukemia? [PDF]

, 1999
The differential staining cytotoxicity (DISC) assay involves in vitro drug panel testing against patient tumor cells to identify optimal therapy. This observational study investigated whether DISC assay guided treatment could improve outcome in patients ...
Bosanquet, A.G., Drummond, M.F., Mason, J.M., Sheldon, T.A.   +3 more
core   +1 more source

Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. [PDF]

, 2017
Signaling via the B cell receptor (BCR) plays an important role in the pathogenesis and progression of chronic lymphocytic leukemia (CLL). This is underscored by the clinical effectiveness of ibrutinib, an inhibitor of Bruton's tyrosine kinase (BTK) that
Chen, L, Chen, Y, Choi, MY, Cui, B, Kipps, TJ, Rassenti, LZ, Widhopf Ii, GF, Wu, Christina, Yu, J, Zhang, L   +9 more
core  

Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States. [PDF]

, 2017
BACKGROUND: Median age at diagnosis of patients with chronic lymphocytic leukemia (CLL) is \u3e 70 years. However, the majority of clinical trials do not reflect the demographics of CLL patients treated in the community.
Bhushan, Shriya, Davids, Matthew S., Flick, E. Dawn, Flowers, Christopher R., Grinblatt, David L., Kiselev, Pavel, Lamanna, Nicole, Mato, Anthony, Nabhan, Chadi, Sharman, Jeff P., Sullivan, Kristen, Swern, Arlene S., Weiss, Mark A.   +12 more
core   +3 more sources

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.

Blood, 2018
We previously reported durable responses and manageable safety of ibrutinib from a 3-year follow-up of treatment-naïve (TN) older patients (≥65 years of age) and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia/small lymphocytic ...
S. O'brien, R. Furman, S. Coutre, I. Flinn, J. Burger, K. Blum, J. Sharman, W. Wierda, Jeffrey A Jones, Weiqiang Zhao, N. Heerema, A. Johnson, Ying Luan, D. James, A. Chu, J. Byrd   +15 more
semanticscholar   +1 more source

Telomere protein complexes and their role in lymphoid malignancies [PDF]

, 2017
Telomeres are highly regulated and dynamic complexes that protect the genomic DNA and prevent the end of linear chromosomes from being misrecognized as a broken DNA.
Dos Santos, Patricia Carolina, Panero, Julieta, Slavutsky, Irma Rosa   +2 more
core  

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.

New England Journal of Medicine, 2011
BACKGROUND The somatic genetic basis of chronic lymphocytic leukemia, a common and clinically heterogeneous leukemia occurring in adults, remains poorly understood.
Lili Wang, M. Lawrence, Youzhong Wan, P. Stojanov, C. Sougnez, K. Stevenson, L. Werner, A. Sivachenko, D. DeLuca, Li Zhang, Wandi Zhang, Alexander Vartanov, S. Fernandes, Natalie R. Goldstein, Eric G. Folco, K. Cibulskis, B. Tesar, Quinlan L. Sievers, Erica Shefler, S. Gabriel, N. Hacohen, R. Reed, M. Meyerson, T. Golub, E. Lander, D. Neuberg, Jennifer R. Brown, G. Getz, Catherine J. Wu   +28 more
semanticscholar   +1 more source

Towards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic Agents In Vitro [PDF]

, 2015
It has been previously revealed that statins used at high concentrations display antileukemic potential towards chronic lymphocytic leukemia (CLL) cells.
Błoński, Jerzy Z., Cebula-Obrzut, Barbara, Hikisz, Paweł, Kaźmierczuk, Arleta, Kiliańska, Zofia M., Misiewicz, Małgorzata, Robak, Paweł, Smolewski, Piotr, Wawrzyniak, Ewa, Żołnierczyk, Jolanta   +9 more
core   +3 more sources

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

Blood, 1996
N 1988, THE National Cancer Institute-sponsored Working Group (NCI-WC) on chronic lymphocytic leukemia (CLL) published guidelines for the design and conduct of clinical trials in CLL with two major objectives: first, to facilitate comparisons of results ...
B. Cheson, J. Bennett, M. Grever, N. Kay, M. Keating, S. O'brien, K. Rai   +6 more
semanticscholar   +1 more source

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.

Cancer Discovery, 2018
The BCL2 inhibitor venetoclax induces high rates of durable remission in patients with previously treated chronic lymphocytic leukemia (CLL). However, despite continuous daily treatment, leukemia recurs in most patients.
P. Blombery, M. Anderson, Jia-Nan Gong, R. Thijssen, R. Birkinshaw, E. Thompson, Charis E. Teh, Tamia Nguyen, Zhen Xu, C. Flensburg, T. E. Lew, I. Majewski, D. Gray, D. Westerman, C. Tam, J. Seymour, P. Czabotar, D. Huang, A. Roberts   +18 more
semanticscholar   +1 more source

Questions and answers about leukemia [PDF]

Leukemia is cancer of the white blood cells. It develops in the bone marrow and spreads into the blood and to other organs. There are several types of leukemia. They are grouped in two ways: by how rapidly the disease develops (acute vs. chronic leukemia)

core